Sarah Cannon Research Institute

The cloud-based personalized medicine software company will stay in Cambridge, Massachusetts and will become a wholly-owned subsidiary of the institute.

Under the agreement, researchers can use Foundation Medicine's assays to select patients eligible for Sarah Cannon Research Institute's clinical studies.

Researchers presented data suggesting that pharma companies are using basket studies to identify molecularly defined patient subsets who might benefit from their drugs.

The partners will explore the use of Biocept's liquid biopsy technology to identify and detect biomarkers in ER-positive breast cancer patients.

CHICAGO (GenomeWeb) – Research presented at the annual meeting of the American Society of Clinical Oncology this week included a wealth of data from programs using next-generation sequencing to guide treatment for cancer patients.

This article has been updated with additional information from Sarah Cannon Research Institute.Originally published July 2.

NEW YORK (GenomeWeb News) – Sarah Cannon Research Institute and AstraZeneca said today that they will work together to advance drugs in AstraZeneca's pipeline with a personalized medicine strategy.

UCL-Advanced Diagnostics, diagnostic service provider of the University College London Cancer Institute, has opened a new molecular profiling laboratory that will offer a sequencing-based multi-gene test for cancer patients in the UK and elsewhere.

In a prospective study published this month, patients with cancer of unknown primary who were tested using BioTheranostics' CancerType ID assay, and who then received chemotherapy specific to their predicted tumor of origin, survived longer on average than expected for standard C

An artificial intelligence-based analysis suggests a third group of ancient hominins likely interbred with human ancestors, according to Popular Mechanics.

In Science this week: reduction in bee phylogenetic diversity, and more.

The New York Times Magazine looks into paleogenomics and how it is revising what's know about human history, but also possibly ignoring lessons learned by archaeologists.

The Economist reports on Synthorx's efforts to use expanded DNA bases they generated to develop a new cancer drug.